Literature DB >> 12067685

Mediastinal (thymic) large B-cell lymphoma: where do we stand?

Thomas F E Barth1, Frank Leithäuser, Stefan Joos, Martin Bentz, Peter Möller.   

Abstract

Mediastinal (thymic) B-cell lymphoma (MBL) is a locally highly aggressive tumour that was first definitively described in the early 1980s. The incidence of MBL is low, which made disease characterisation difficult initially. However, MBL has several peculiar clinical, morphological, immunological, and genetic features. Collectively, these characteristics distinguish it from other diffuse, large B-cell lymphomas. Consequently, MBL has become a defined subtype of diffuse large B-cell lymphoma with its own code (9679/3) in the International Classification of Diseases. New insights into the biological and clinical aspects of MBL have been gained from the study of large numbers of cases. Nevertheless, the histogenesis of the disease is not yet fully understood. We review the available data on MBL with special emphasis on its morphological, immunological, and genetic properties. Also discussed are recent data on molecular genetics, biology, and treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12067685     DOI: 10.1016/s1470-2045(02)00714-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  35 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Cardiac, aortic, and esophageal involvement of a large lymphoma.

Authors:  Melih Kaptanoglu; Aydin Nadir; Omer Topcu; Sahande Elagoz; Cesur Gumus
Journal:  Tex Heart Inst J       Date:  2004

Review 3.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

4.  Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.

Authors:  Robin A Roberts; George Wright; Andreas R Rosenwald; Marina A Jaramillo; Thomas M Grogan; Thomas P Miller; Yvette Frutiger; Wing C Chan; Randy D Gascoyne; German Ott; H Konrad Muller-Hermelink; Louis M Staudt; Lisa M Rimsza
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

5.  Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.

Authors:  Min Shi; Margaretha G M Roemer; Bjoern Chapuy; Xiaoyun Liao; Heather Sun; Geraldine S Pinkus; Margaret A Shipp; Gordon J Freeman; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

Review 6.  Primary mediastinal (thymic) large B cell lymphoma with aberrant expression of CD3: a case report with review of the literature.

Authors:  Endi Wang; Maggie Stoecker
Journal:  Int J Hematol       Date:  2010-02-04       Impact factor: 2.490

Review 7.  Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies.

Authors:  Pier Luigi Zinzani; Pier Paolo Piccaluga
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 8.  The histological classification of diffuse large B-cell lymphomas.

Authors:  Yi Xie; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Hematol       Date:  2015-01-17       Impact factor: 3.851

Review 9.  [Grayzone lymphoma. Clinical relevance].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

10.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.